EWING, NJ--(Marketwire - September 17, 2008) - DOR BioPharma, Inc. (DOR or the Company) (OTCBB: DORB), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today the formation of a European Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it relates to the ongoing development of orBec® for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD).
